PhaseBio Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as CBO

PhaseBio Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as CBO

MALVERN, PA – PhaseBio Pharmaceuticals, Inc, a privately held, clinical-stage biotechnology company developing novel drugs to treat metabolic and cardiovascular diseases, announced today that Jonathan P. Mow has been appointed Chief Business Officer. Mr. Mow has more than 20 years of experience in business development and commercial operations, most recently with Amylin Pharmaceuticals, where he implemented the strategy that resulted in Amylin's $7 billion acquisition by Bristol-Myers Squibb and Astra Zeneca.

"PhaseBio has continued to move multiple products into the clinic.  We are now ready to drive the strategic plans to bring these important advances to patients and Jonathan's extensive commercial planning and deal making experience will position PhaseBio for significant growth," said Christopher Prior, Ph.D., CEO of PhaseBio.
Prior to joining PhaseBio, Mr. Mow was Vice President, Business Development, for Amylin Pharmaceuticals, where he was responsible for business development and strategic planning resulting in completion of numerous transactions.  Notably, Mr. Mow was responsible for implementing a partnership with Takeda for the treatment of obesity through a multi-asset development and commercialization collaboration.  Prior to joining Amylin, Jonathan was co-founder and a member of the board of directors of Corus Pharma, where he served as Vice President, Commercial and Business Development until Corus's sale to Gilead in 2006.  Earlier in his career, Jonathan was responsible for Business Development at PathoGenesis Corporation until the acquisition of the company by Chiron. He has also held various roles in marketing and strategic planning at Bristol-Myers Squibb, Wyeth/Lederle International and Syntex Laboratories.

Mr. Mow has an MBA from the Tepper School of Management at Carnegie Mellon University and a Bachelor of Science from the University of California, Berkeley.

"I am confident that PhaseBio has the cutting edge technology and differentiated product pipeline to make substantive advances in the treatment of diabetes and cardiovascular disease.  The company's clinical development programs will achieve significant milestones over the next six months.  I look forward to exploring the many possibilities we will have with corporate partners and the investment community," said Jonathan Mow, Chief Business Officer of PhaseBio.

About PhaseBio Pharmaceuticals, Inc.

PhaseBio is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes, metabolic and cardiovascular disease.  The company's proprietary platform technology uses elastin-like biopolymers to increase the half-life, bioavailability, efficacy and ease of administration of therapeutic drugs and to reduce their side effects.  ELPs have been engineered to control the rate of absorption into the circulation, which results in a steady state pharmacokinetic profile, exhibiting a unique combination of slow absorption and prolonged half-life to provide an optimal drug exposure.  The company's lead development candidates are PB-1023 (formerly known as Glymera), a weekly GLP-1 analogue for type 2 diabetes; Vasomera, a vasoactive intestinal peptide (VIP) agonist for acute and chronic heart failure and pulmonary arterial hypertension; and Insumera, a novel mature insulin ELP-fusion.  In August 2012, the company announced that it had initiated a multicenter, randomized placebo and active comparator controlled Phase 2b trial to evaluate the use of PB1023 for the treatment of uncontrolled Type 2 diabetes.  PhaseBio is privately owned with headquarters and research laboratories in Malvern, Pennsylvania.


Erika Barron
PhaseBio Pharmaceuticals, Inc.
Ph. 610-981-6500
[email protected]

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.